Eli Lilly and Company — SEC Form 4 Filings
SEC Form 4 Data
Track insider buying and selling activity for Eli Lilly and Company (LLY). Data sourced from SEC EDGAR Form 4 filings and analyzed by StoxPulse AI for significance.
17
$173K total
3
$15.8M total
5.7x
Bullish Signal
20
Form 4 transactions
Buy − Sell value
Sale · May 6, 2026
Sulzberger · Buy
Eli Lilly and Company insiders filed 20 Form 4 transactions in the period analyzed: 17 purchases totaling $173K and 3 sales totaling $15.8M. That puts the buy-to-sell ratio at 5.67, which we read as bullish on a directional basis.
The most active filer was Sulzberger Gabrielle with 4 transactions in this window. 17 of the 20 filings are flagged as routine — typically 10b5-1 scheduled trades rather than discretionary signals.
Form 4 filings are point-in-time disclosures and do not constitute investment advice. Routine sales under pre-arranged 10b5-1 plans should not be read as bearish.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Sulzberger Gabrielle | Director | Buy | 5.018 | $988.09 | $5K | 2026-05-18 |
| LUCIANO JUAN R | Director | Buy | 16.109 | $988.09 | $16K | 2026-05-18 |
| Fyrwald J Erik | Director | Buy | 10.036 | $988.09 | $10K | 2026-05-18 |
| Alvarez Ralph | Director | Buy | 12.566 | $988.09 | $12K | 2026-05-18 |
| LILLY ENDOWMENT INC | Former 10% Shareholder | Sale | 13,620 | $995.23 | $13.6M | 2026-05-06 |
| LILLY ENDOWMENT INC | Former 10% Shareholder | Sale | 2,208 | $996.18 | $2.2M | 2026-05-06 |
| Sulzberger Gabrielle | Director | Buy | 5.39 | $919.90 | $5K | 2026-04-20 |
| LUCIANO JUAN R | Director | Buy | 17.303 | $919.90 | $16K | 2026-04-20 |
| Fyrwald J Erik | Director | Buy | 10.78 | $919.90 | $10K | 2026-04-20 |
| Alvarez Ralph | Director | Buy | 13.498 | $919.90 | $12K | 2026-04-20 |
| Sulzberger Gabrielle | Director | Buy | 5.013 | $989.12 | $5K | 2026-03-16 |
| LUCIANO JUAN R | Director | Buy | 16.092 | $989.12 | $16K | 2026-03-16 |
| Fyrwald J Erik | Director | Buy | 10.026 | $989.12 | $10K | 2026-03-16 |
| Alvarez Ralph | Director | Buy | 12.553 | $989.12 | $12K | 2026-03-16 |
| Dozier Eric | EVP, Chief People Officer | Sale | 481 | $0.00 | $0.00 | 2026-02-19 |
| Sulzberger Gabrielle | Director | Buy | 4.786 | $1036.05 | $5K | 2026-02-17 |
| LUCIANO JUAN R | Director | Buy | 15.363 | $1036.05 | $16K | 2026-02-17 |
| Fyrwald J Erik | Director | Buy | 9.572 | $1036.05 | $10K | 2026-02-17 |
| Alvarez Ralph | Director | Buy | 11.985 | $1036.05 | $12K | 2026-02-17 |
| Zakrowski Donald A | SVP, Finance, & CAO | Buy | 184 | $0.00 | $0.00 | 2026-02-16 |
Insider trading data for Eli Lilly and Company (LLY) is sourced directly from SEC Form 4 filings on the EDGAR database. Corporate insiders — including directors, officers, and shareholders owning more than 10% of the company — are legally required to report their transactions within two business days.
Insider purchases are often considered a bullish signal because executives are using their own money to buy shares, suggesting they believe the stock is undervalued. Insider sales, on the other hand, are more nuanced — they can reflect routine diversification plans (known as 10b5-1 plans), tax obligations, or genuine concerns about the company's outlook.
StoxPulse's AI system analyzes each LLY insider transaction to determine whether it appears routine or notable. We track the buy/sell ratio, total transaction values, and patterns over time to provide a clear picture of insider sentiment for Eli Lilly and Company.
AI earnings, financials, news & more
Translate any filing into plain English
Disclaimer: Insider trading data for Eli Lilly and Company (LLY) is sourced from SEC Form 4 filings and is provided for informational purposes only. Insider transactions should not be the sole basis for investment decisions. Always consult a qualified financial advisor.
Join the waitlist to receive instant AI notifications when Eli Lilly and Company insiders buy or sell shares.
Join the Waitlist